Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease
Overview
- Phase
- Phase 4
- Intervention
- pioglitazone group
- Conditions
- LVM
- Sponsor
- Xiang Guang-da
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- The changes of LVM
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
Cardiovascular complications account for the highest mortality in type 2 diabetic patients, mainly due to ischeamia heart disease (IHD). Most of the attention in treating IHD in type 2 diabetes is understandably directed toward treating coronary artery conditions. However there are other treatable culprits in these patients.
Left ventricular hypertrophy (LVH) is widespread in type 2 diabetic patients with IHD, even in the absence of hypertension. It is a strong predictor of cardiovascular events and all-cause mortality. In one study, the presence of LVH was a stronger predictor of mortality than either multivessel coronary disease or impaired left ventricular function. Regression of LVH has been associated with an improved prognosis, independent of change in blood pressure (BP). Therefore, cardiovascular events and mortality in type 2 diabetes with IHD might will be reduced if we can find novel therapies to regress LVH.
Pioglitazone can improve atherosclerosis. Therefore, we hypothesied that pioglitazone can regress the left ventricular mass (LVM) in type 2 diabetes with IHD.Therefore, in this study, we will treat patients with pioglitazone, and we will also metformin as control.
Investigators
Xiang Guang-da
Pioglitazone regress the left ventricular mass in normotensive type 2 diabetic patients with ischeamia heart disease
Wuhan General Hospital of Guangzhou Military Command
Eligibility Criteria
Inclusion Criteria
- •type 2 diabetes
- •aged 40～75 years old
Exclusion Criteria
- •heart failure
- •renal failure
- •hypertension (\>130/80 mmHg)
- •hemoglobin A1c 9%
Arms & Interventions
Pioglitazone group
Pioglitazone 15 mg/day will be given in this group for 9 months
Intervention: pioglitazone group
Metformin group
Metformin 0.85 twice daily will be given in this group for 9 months as control.
Intervention: Metformin group
Outcomes
Primary Outcomes
The changes of LVM
Time Frame: The LVM will be measured at baseline, 6 momth and 9 month
Secondary Outcomes
- The changes of endothelial function(The endothelial function will be measured at baseline, 6 month and 9 month)